Your session is about to expire
← Back to Search
Connective Tissue Matrix
CTM Shoulder Injection for Shoulder Osteoarthritis (HC22-1 Trial)
Phase 1
Waitlist Available
Research Sponsored by Indiana Hand to Shoulder Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients receiving a CTM injection for their initial treatment
Radiographic documented Glenohumeral osteoarthritis (grade 1-3)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
HC22-1 Trial Summary
This trial is testing a tissue allograft to treat shoulder pain due to arthritis. It will measure pain and shoulder score at follow up intervals to determine success rate.
Who is the study for?
This trial is for individuals with shoulder osteoarthritis confirmed by X-rays. Participants will receive a single CTM injection guided by imaging to help with their condition. The study aims to track pain relief and improved shoulder function over time.Check my eligibility
What is being tested?
The trial tests the effectiveness of a human placental connective-tissue matrix (CTM) injection in managing shoulder osteoarthritis. Success rates are measured using pain and shoulder function scores at multiple intervals up to one year post-injection.See study design
What are the potential side effects?
Potential side effects were not explicitly provided, but as with any injection, there may be risks such as pain at the injection site, infection, allergic reactions or no improvement in joint symptoms.
HC22-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am getting a CTM injection as my first treatment.
Select...
I have been diagnosed with mild to moderate shoulder arthritis.
HC22-1 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Likert Pain Scale
Oxford Shoulder Score
HC22-1 Trial Design
1Treatment groups
Experimental Treatment
Group I: CTM Shoulder InjectionExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Indiana Hand to Shoulder CenterLead Sponsor
8 Previous Clinical Trials
320 Total Patients Enrolled
CTM BiomedicalIndustry Sponsor
3 Previous Clinical Trials
119 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger